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2019‐nCoV

:   2019 new coronavirus

ACE2

:   angiotensin converting enzyme II

ALT

:   alanine transaminase

AST

:   aspartate aminotransferase

COVID‐19

:   coronavirus disease 2019

CRP

:   C‐reactive protein

CT

:   computed tomographic

ESR

:   erythrocyte sedimentation rate

Key pointsLiver injury is prevalent in COVID‐19 patients.Severe Lung lesions on CT might be related to higher incidence of liver injury.

1. INTRODUCTION {#liv14449-sec-0006}
===============

Coronavirus disease 2019 (COVID‐19) was first diagnosed in Wuhan, Hubei province in China in 2019 and subsequently spread worldwide. Spread of COVID‐19 is via airborne droplets, intimate contact, etc and infection results in pneumonia.[^1^](#liv14449-bib-0001){ref-type="ref"}, [^2^](#liv14449-bib-0002){ref-type="ref"} COVID‐19 was documented in approximately 80 000 persons in China, resulting in more than 2800 deaths by the end of February 2020. Now COVID‐19 is an ongoing public health emergency of international significance. Previous studies have found that ICU patients with COVID‐19 had high risk for liver injury, but the cause of liver injury was not further analysed.[^3^](#liv14449-bib-0003){ref-type="ref"}, [^4^](#liv14449-bib-0004){ref-type="ref"} In addition, previous studies had focused on liver injury in ICU patients, but less focused on non‐ICU patients. This retrospective study included patients with confirmed COVID‐19 in general ward, and intended to explore the possible influencing factors of liver injury and provided further information for mechanism.

2. MATERIALS AND METHODS {#liv14449-sec-0007}
========================

2.1. Patients {#liv14449-sec-0008}
-------------

The retrospective study was conducted in non‐ICU Ward at Wuhan Jinyintan Hospital. All consecutive discharged patients treated by Fujian Medical Team to aid Hubei province were enrolled in the study between February 2, 2020 and February 23, 2020. Jinyintan Hospital, located in Wuhan, Hubei Province is responsible for the treatments for COVID‐19 assigned by the government. Including criteria: (a) All patients enrolled were diagnosed according to World Health Organization interim guidance with laboratory‐identified COVID‐19,[^5^](#liv14449-bib-0005){ref-type="ref"} (b) with completed clinical data. Patients with viral hepatitis, alcoholic liver disease, liver malignancy or other known chronic liver disease were excluded from this study. This retrospective study was approved by the Ethics Committee of the Jinyintan Hospital, Wuhan province.

The clinical data were collected from electronic medical records of Jinyintan Hospital. The clinical data were collected as follows: age, gender, chronic medical illness, symptoms, laboratory findings, chest computed tomographic (CT) scans and the duration of hospital stays. The data were collected and reviewed by a trained team of physicians.

2.2. Experimental grouping {#liv14449-sec-0009}
--------------------------

The patients were divided into moderate group and severe group according to the criteria of the diagnosis and treatment programme of novel coronavirus pneumonia (Trial sixth Edition).[^6^](#liv14449-bib-0006){ref-type="ref"} If the clinical dates met any of the following: (a) Respiratory distress, breathing frequency ≥ 30 breaths/min; (b) In resting state, means oxygen saturation ≤93% and (c) Arterial blood oxygen partial pressure/oxygen concentration ≤300 mm Hg (1 mm Hg = 0.133 kPa), the patient were included in severe group. Others were included in moderate group.

The clinical characteristics of patients with liver injury and those without liver injury were compared. All the patients with elevated levels of alanine transaminase (ALT), aspartate aminotransferase (AST) or bilirubin were defined as liver injury.

2.3. CT image acquisition and scoring {#liv14449-sec-0010}
-------------------------------------

All Patients completed lung CT scan within 2 days after admission. CT scans were reviewed and findings were scored prospectively by two respiratory and critical care physician in consensus. CT scores were assessed based on previous reports.[^7^](#liv14449-bib-0007){ref-type="ref"} To quantify the extent of pneumonia, CT scores were assigned on the basis of the area involved (Table [1](#liv14449-tbl-0001){ref-type="table"}). There was a score of 0‐5 for each lobe, with a total possible score of 0‐25.

###### 

System for lung CT scoring

  Score   Definition
  ------- -----------------------------------------------------
  0       None
  1       5% of lobe[^a^](#liv14449-note-0002){ref-type="fn"}
  2       5%--25% of lobe
  3       26%--49% of lobe
  4       50%--75% of lobe
  5       75% of lobe

Minimal but not normal.
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2.4. Statistical analysis {#liv14449-sec-0011}
-------------------------

Categorical variables were described as percentages, and continuous variables were described using mean ± SD or median (interquartile range) value. Means for continuous variables were compared using independent group *t* tests when the data were normally distributed; otherwise, the Mann--Whitney test was used. Categorical variables were compared using the *χ* ^2^ test; Fisher exact test was used when the data were limited. Furthermore, stepwise logistic regression models were built to identify independent risks of liver injury. All statistical analyses were performed using SPSS 22.0. The significance was recognized at a *P* \< .05.

3. RESULTS {#liv14449-sec-0012}
==========

A total of 79 cases with confirmed COVID‐19 were included in this study. The median age was 60.0 years (range 27‐87 years), and 44 (55.7%) were male. 34.5% patients met the diagnostic criteria of severe COVID‐19. No patient needed invasive mechanical ventilation. The median durations from initial symptoms to admission were 12 days. Common symptoms included cough (70.9%), fever (70.9%) and dyspnoea (50.6%). Of all the patients, 21 (26.5%) had 1 or more coexisting chronic medical conditions. There was no significant difference in gender, age, symptoms and underlying disease between the severe group and the general group (*P* \> .05; Table [2](#liv14449-tbl-0002){ref-type="table"}). The levels of average CRP, D‐dimer, Fibrinogen and erythrocyte sedimentation rate (ESR) elevated. The levels of average of Lymphocyte counts decreased. The median time from the admission to first negative result of pharyngeal swab was 5.1 days. The average length of hospital stay was about 11.9 days.

###### 

Clinical characteristics of non‐ICU hospitalized patients with 2019 novel coronavirus pneumonia

                                              Overall (n = 79)    Moderate (n = 51)   Severe (n = 28)    *P* value
  ------------------------------------------- ------------------- ------------------- ------------------ -----------
  Ages (y)                                    60.0 (48.0‐66.0)    59.0 (46.0‐66.0)    62.5 (50.5‐67.8)   .59
  Male gender (%)                             55.7                51.0                64.3               .34
  *Chronic medical illness*                                                                              
  Hypertension (%)                            17.7                19.6                14.3               .56
  Diabetes mellitus (%)                       10.1                11.8                7.1                .16
  CHD (%)                                     8.9                 9.8                 7.1                .22
  Onset time (d)                              12 (10‐15)          11 (8‐15)           12 (10‐15)         .21
  *Symptom*                                                                                              
  Fever (%)                                   70.9                62.7                85.7               .03
  Cough (%)                                   70.9                70.6                71.4               .94
  Expectoration (%)                           25.3                25.5                25.0               .96
  Dyspnoea (%)                                50.6                47.1                57.1               .39
  Diarrhoea (%)                               8.9                 5.9                 14.3               .21
  White blood cell count (×10⁹ cells per L)   5.2 (4.3‐6.9)       4.9 (4.1‐6.8)       5.5 (4.5‐7.7)      .06
  Lymphocyte count (×10⁹ cells per L)         1.2 (0.9‐1.6)       1.2 (0.9‐1.6)       1.1 (0.7‐1.6)      .56
  Neutrophil count (×10⁹ cells per L)         3.7 (2.8‐5.3)       3.7 (2.7‐5.1)       3.8 (3.2‐5.7)      .20
  Total bilirubin (µmol/L)                    13.6 (8.8‐17.6)     13.9 (8.9‐18.7)     12.7 (8.1‐15.4)    .38
  ALT (IU/L, baseline)                        34 (18‐67)          30.0 (21.0‐43.5)    36.5 (17.5‐71.5)   .59
  ALT (IU/L, post‐treatment)                  26 (20‐31)          28 (19‐34)          25 (20‐32)         .63
  AST (IU/L, baseline)                        30 (23‐50)          28 (22‐48)          35 (25‐55)         .23
  AST (IU/L, post‐treatment)                  28 (20‐33)          26 (22‐30)          26 (23‐32)         .35
  γ‐GT (IU/L)                                 31.5 (19.0‐81.3)    25.5 (18.5‐97.3)    35.5 (23.8‐82.8)   .50
  ALP (IU/L)                                  79.0 (59.0‐100.0)   80 (60‐114.3)       75.5 (59.0‐93.0)   .56
  Creatinine (µmol/L)                         69.8 (59.0‐79.6)    70.2 (57.7‐79.3)    68.7 (60.8‐80.3)   .63
  C‐reactive protein (mg/L)                   13.9 (3.1‐51.9)     11.0 (2.3‐32.0)     35.2 (6.5‐61.7)    .07
  ESR (mm/h)                                  39 (24‐58)          36.0 (19.6‐52.8)    45.4 (26.5‐65.5)   .09
  D‐dimer (µg/mL)                             0.69 (0.33‐1.35)    0.67 (0.31‐1.34)    0.70 (0.43‐2.36)   .46

Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; CHD, Coronary heart disease; CT, computerized tomography; ESR, erythrocyte sedimentation rate; γ‐GT, Gamma‐Glutamyltransferase.
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31.6% patients had elevated ALT, 35.4% patients had elevated AST and 5.1% had elevated bilirubin. The patients were divided into two groups based on the presence or absence of liver injury. The clinical characteristics of the two groups were compared. The ratio of male was higher in patients with liver damage than in patients without liver injury (*P* \< .05). There were increased levels of white blood cell counts, neutrophils and CRP in the liver injury group (*P* \< .05). The CT score of the liver injury group was significantly higher than that of the non‐liver injury group (*P* \< .05). The incidences of liver injury were 13.3%, 36.4% and 77.8% in the patients with CT scores of \<5, 5‐15 and \>15 points respectively (*χ* ^2^ = 10.06, *P* = .007). All patients got improvement in clinical symptoms, negative coronavirus test and were discharged in this study, while patients with liver damage had longer length of stay than patients without liver injury (*P* \< .05). The liver enzymes after treatment between patients with and without liver injury were not significantly different (Table [3](#liv14449-tbl-0003){ref-type="table"}).

###### 

Clinical characteristics of patients with 2019 novel coronavirus pneumonia and liver injury

                                                Patients without liver injury (n = 50)   Patients with liver injury (n = 29)   *P* value
  --------------------------------------------- ---------------------------------------- ------------------------------------- -----------
  Age (y)                                       56 (45.5‐65.0)                           62.0 (46.0‐67.0)                      .36
  Male gender (%)                               44.7                                     72.4                                  .02
  *Chronic medical illness*                                                                                                    
  Hypertension (%)                              19.1                                     17.2                                  .83
  Diabetes mellitus (%)                         10.6                                     10.3                                  .97
  CHD (%)                                       10.6                                     6.9                                   .59
  *Symptom*                                                                                                                    
  Fever (%)                                     62.0                                     86.2                                  .02
  Cough (%)                                     66.0                                     75.9                                  .45
  Expectoration (%)                             23.4                                     24.1                                  .57
  Dyspnoea (%)                                  51.1                                     44.8                                  .39
  Diarrhoea (%)                                 8.5                                      6.9                                   .58
  White blood cell count (×10^9^ cells per L)   4.8 (4.1‐6.1)                            6.3 (4.6‐7.7)                         .03
  Lymphocyte count (×10^9^ cells per L)         1.3 (1.0‐1.7)                            1.2 (0.8‐1.5)                         .13
  Neutrophil count (×10^9^ cells per L)         3.6 (2.7‐4.5)                            4.7 (3.5‐5.7)                         .03
  ALT (IU/L, baseline)                          23 (14‐33)                               74 (61‐116)                           .001
  ALT (IU/L, post‐treatment)                    24 (22,27)                               27 (24,31)                            .15
  AST (IU/L, baseline)                          25 (20‐30)                               59 (46.5‐74.5)                        \<.001
  AST (IU/L, post‐treatment)                    23 (20,30)                               28 (22,30)                            .18
  γ‐GT (IU/L)                                   23.0 (18.5‐35.5)                         97.0 (55.0‐173.0)                     \<.001
  ALP (IU/L)                                    76.0 (56.8‐92.0)                         89.0 (71.0‐143.0)                     .02
  C‐reactive protein (mg/L)                     6.0 (1.6‐39.4)                           31.1 (13.5‐70.5)                      .01
  ESR (mm/h)                                    35.0 (20.5‐55.9)                         45.0 (26.0‐61.0)                      .33
  D‐dimer (µg/mL)                               0.5 (0.3‐1.3)                            0.9 (0.6‐2.6)                         .11
  CT score                                      7.5 (5.0‐9.0)                            11 (10.0‐17.0)                        .00
  Length of stay (d)                            11.4 (8.5‐14.0)                          15.4 (11.0‐16.8)                      .01

Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; CHD, Coronary heart disease; CT, computerized tomography; ESR, erythrocyte sedimentation rate; γ‐GT, Gamma‐Glutamyltransferase.
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Table [4](#liv14449-tbl-0004){ref-type="table"} shows the correlations among baseline ALT, AST and the other variables. Both indices were significantly correlated with the ratio of male, CRP and D‐dimer (all *P* \< .05). CT scores, as an expression of the severity of COVID‐19, was also correlated with ALT and AST (*r* = .524, *P* = .000 and *r* = .550, *P* = .000 respectively). And the level of white blood cell counts and neutrophils were correlated with ALT (both *P* \< .05). Finally, stepwise logistic regression suggested that CT scores were an independent predictor for liver injury after adjusting for male, CRP and D‐dimer (odds ratio \[OR\] = 5.265, 95% CI (1.025‐1.371), *P* = .022).

###### 

Spearman\'s rank correlation coefficients between liver enzyme levels (ALT and AST) and clinical characteristics

                                                ALT      AST               
  --------------------------------------------- -------- -------- -------- --------
  Male gender                                   −0.313   .006     −0.242   .035
  Age                                           −0.020   .864     0.012    .920
  White blood cell count (×10^9^ cells per L)   0.257    .026     0.177    .133
  Lymphocyte count (×10^9^ cells per L)         −0.030   .800     −0.224   .054
  Neutrophil count (×10^9^ cells per L)         0.278    .026     0.218    .083
  C‐reactive protein (mg/L)                     0.328    .010     0.428    .001
  ESR (mm/h)                                    0.234    .075     0.251    .055
  D‐dimer (µg/mL)                               0.317    .013     0.290    .025
  CT score                                      0.524    \<.001   0.550    \<.001

Abbreviations: ALT, alanine transaminase; AST, aspartate aminotransferase; CT, computerized tomography; ESR, erythrocyte sedimentation rate.
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4. DISCUSSION {#liv14449-sec-0013}
=============

This retrospective study found that nearly 1/3 non‐ICU hospitalized patients with COVID‐19 had liver injury. Males and those who had higher levels of white blood cells, neutrophils, CRP and CT lesions are more likely to have liver injury.

Previous studies have found that liver injury was common in critically ill patients with COVID‐19.[^4^](#liv14449-bib-0004){ref-type="ref"}, [^8^](#liv14449-bib-0008){ref-type="ref"}, [^9^](#liv14449-bib-0009){ref-type="ref"}, [^10^](#liv14449-bib-0010){ref-type="ref"} Autopsy results of patients with COVID‐19 revealed degeneration of hepatocytes, focal necrosis with neutrophil infiltration; lymphocytic and monocyte infiltration in the hepatic manifold area and microthrombosis. The results of the study by Huang et al suggested that the median values of ALT and AST in the non‐ICU group were 27.0 (19.5‐40.0) and 34.0 (24.0‐40.5) U/L, respectively, which were at normal range in ICU group; the median values of ALT and AST in the group were 49.0 (29.0 to 115.0) and 44.0 (30.0 to 70) U/L respectively.[^9^](#liv14449-bib-0009){ref-type="ref"} The study failed to investigate the cause of elevated serum transaminase. Wang et al[^9^](#liv14449-bib-0009){ref-type="ref"} found that the median AST of ICU patients was 52 (30‐70) U/L, but the study did not explore the cause of abnormal AST in the ICU group. In this study, we focused on non‐ICU residents. Although the median values of ALT and AST were in the normal range, nearly one‐third patients had elevated ALT or AST. The clinical findings suggested that even in non‐critical COVID‐19 patients, liver injury was common, while most patients had slight elevated aminotransferases and good prognosis.

The mechanisms of liver injury that occurred during 2019 new coronavirus (2019‐nCoV) infection remain largely unclear.[^4^](#liv14449-bib-0004){ref-type="ref"} To explore the reasons of liver injury in patients, we compared the clinical characteristics of patients with and without liver injury. To avoid the impact of previous liver disease on the results of the study, we excluded patients with a previous history of liver disease during the patient enrolment process. Although the median time from symptom onset to hospitalization was 12 days, none of these patients had undergone regular antiviral therapy, so possibility of liver injury in these patients resulting from drug may be excluded. COVID‐19 with liver injury group had increased white blood cells, neutrophils and CRP. The results indicated that the levels of body\'s inflammation may have certain effects on the liver function of COVID‐19. The severity of lung CT lesions can reflect the severity of COVID‐19 to a certain extent. In this study, we found that COVID‐19 with liver injury had higher CT score; and CT score was the predictor factor of liver injury in COVID‐19. Although it is not confirmed whether there is a causal relationship between changes in lung CT and liver injury, the above results suggest that patients with severe imaging lesions need to undergo close monitoring of liver function to identify patients with liver damage for early intervention. Liver injury was associated with prolonged hospital stay in our study, so liver damage may be related to prognosis of patients with COVID‐19.

Angiotensin converting enzyme II (ACE2) may also be the main receptor for 2019‐nCoV.[^11^](#liv14449-bib-0011){ref-type="ref"} Single‐cell sequencing showed that ACE2 was mainly expressed in bile duct epithelial cells in normal liver tissues, but very low in hepatocytes; But ACE2 expression is upregulated in a mouse model of acute liver injury.[^12^](#liv14449-bib-0012){ref-type="ref"} Proliferation of bile duct epithelium in the manifold area is involved in liver damage repair. This phenomenon may suggest that ACE2‐expressing bile duct epithelial cells dedifferentiate and proliferate and become new liver cells. During this compensatory process, some neonatal hepatocytes still retain the characteristics of expressing ACE2 and are susceptible to 2019‐nCoV.[^13^](#liv14449-bib-0013){ref-type="ref"} This may be the cause of liver injury in COVID‐19. The study found a higher proportion of male in COVID‐19 with liver damage. Whether it is related to the number of ACE2 receptors in male hepatocytes remains unclear. It is worth to further investigate in the future.

The study had some limitations. (a) The study was a single‐centre, retrospective study with a small sample size. The nature of this study might compromise the conclusion. (b) Underlying liver diseases were the major confounding factors in this study. Although we tried to eliminate the influence of chronic liver disease by excluding viral hepatitis, alcoholic hepatitis or malignancy, we still could not completely rule out the impact of non‐alcoholic fatty liver disease. The diagnosis of fatty liver disease requires the radiology examination in liver, which cannot be widely carried out when the medical resource is limited during the outbreak of COVID‐19. However, the liver enzymes after treatment between patients with and without liver injury were not significantly different, suggesting the elevated liver enzymes on admission were more likely to be resulted from COVID‐19 infection than any other underlying liver disease.

The results of this retrospective study suggested that COVID‐19 with liver injury in non‐ICU hospitalized patients was common, and it may be related to the degree of CT lesions in the lung. Therefore, the close monitoring and evaluation of liver function in patients with severe pulmonary imaging lesions should be considered.
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